Peer-reviewed veterinary case report
Direct brain infusion of cetuximab iron-oxide nanoparticles to treat
By Freeman, A Courtenay et al.·Published in Journal of neuro-oncology·2018·Veterinary Specialty Care, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Convection-enhanced delivery of cetuximab conjugated iron-oxide nanoparticles for treatment of spontaneous canine intracranial gliomas.
- Species:
- dog
Plain-English summary
Eight dogs with brain tumors called gliomas were treated with a special therapy using cetuximab-conjugated iron-oxide nanoparticles. This treatment was delivered directly to the tumor site, which helped reduce side effects. After one month, the tumors shrank by an average of nearly 55%. While some dogs experienced mild complications that were treated successfully, five dogs had to be euthanized due to worsening neurological symptoms, and one dog passed away in his sleep. On average, the dogs lived about 367 days after the treatment.
People also search for: dog brain tumor treatment · glioma in dogs · cetuximab for dog cancer · dog seizure after brain surgery · canine brain tumor survival rate
Abstract
Cetuximab conjugated iron-oxide nanoparticles (cetuximab-IONPs) have shown both in-vitro and in-vivo anti-tumor efficacy against gliomas. The purpose of this pilot study was to evaluate the safety and potential efficacy of cetuximab-IONPs for treatment of spontaneously occurring intracranial gliomas in canines after convection-enhanced delivery (CED). The use of CED allowed for direct infusion of the cetuximab-IONPs both intratumorally and peritumorally avoiding the blood brain barrier (BBB) and limiting systemic effects. A total of eight dogs participated in the study and only two developed mild post-operative complications, which resolved with medical therapy. All canines underwent a single CED treatment of the cetuximab-IONPs over 3 days and did not receive any further adjuvant treatments. Volumetric analysis showed a median reduction in tumor size of 54.9% by MRI at 1-month (4-6 weeks) follow-up. Five dogs were euthanized due to recurrence of neurological signs other than seizures, two due to recurrent seizures, and one dog died in his sleep. Median survival time after surgery was 248 days (mean 367 days).
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/29350351/